STING agonist - Aduro (Chinook Therapeutics)

STING agonist

Ph. II candidate for met. H&N cancer

from SBDD of endogenous ligand

Clin. Cancer Res.

Aduro (Chinook Therapeutics)

MIW815 (ADU-S100) is a first-in-class STING agonist for cancer immunotherapy. Agonism of the STING (stimulator of IFN genes) receptor, true to its name, leads to stimulation of type I…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.